Ultragenyx Pharmaceutical Inc   (RARE)
Other Ticker:  
Price: $35.6500 $0.48 1.365%
Day's High: $36.08 Week Perf: -2.78 %
Day's Low: $ 35.27 30 Day Perf: -2.49 %
Volume (M): 454 52 Wk High: $ 54.98
Volume (M$): $ 16,171 52 Wk Avg: $42.04
Open: $35.36 52 Wk Low: $33.36

 Market Capitalization (Millions $) 2,528
 Shares Outstanding (Millions) 71
 Employees 1,000
 Revenues (TTM) (Millions $) 403
 Net Income (TTM) (Millions $) -721
 Cash Flow (TTM) (Millions $) -55
 Capital Exp. (TTM) (Millions $) 94

Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of rare and ultra-rare genetic diseases. The company's mission is to provide novel treatments for these rare diseases where there is unmet medical need.

The company was founded in 2010 by Emil Kakkis, who is a pioneer in the field of rare diseases. Ultragenyx started as a small startup and has grown to become one of the leading rare disease biotech companies in the industry. It is headquartered in Novato, California, USA, and has operations in Europe as well.

Ultragenyx is known for its expertise in developing and commercializing rare disease therapies. The company has a robust pipeline of programs that are aimed at addressing a range of rare diseases. Some of the key therapeutic areas the company is focused on include metabolic disorders, skeletal disorders, neurological disorders, and immunology.

One of the company's top products is Mepsevii (vestronidase alfa), which is an enzyme replacement therapy for the treatment of a rare genetic disorder called mucopolysaccharidosis VII (MPS VII). This condition is caused by a deficiency in beta-glucuronidase, which leads to the accumulation of certain complex sugars in the body tissues and organs. Mepsevii works by replacing the missing enzyme in the patient's body, thereby reducing the accumulation of complex sugars and improving the patient's symptoms.

Another product under development by Ultragenyx is DTX301, a gene therapy product for the treatment of ornithine transcarbamylase (OTC) deficiency. OTC deficiency is a rare genetic disorder that affects the body's ability to break down ammonia, leading to its build-up in the blood and tissues. DTX301 works by introducing a healthy copy of the OTC gene into the patient's liver cells, which helps to restore the body's ability to break down ammonia.

Ultragenyx has a strong commitment to research and innovation, and it is constantly exploring new approaches to treat rare diseases. The company has a team of highly experienced professionals who are dedicated to bringing innovative medicines to patients with rare diseases. It has also established partnerships with other companies and organizations in the industry to advance its research and development programs.

In summary, Ultragenyx Pharmaceutical Inc is a biopharmaceutical company that is dedicated to the development and commercialization of innovative therapies for the treatment of rare and ultra-rare genetic diseases. The company has a broad pipeline of rare disease programs, and it is committed to advancing its research and development efforts to bring new treatments to patients in need.

   Company Address: 60 Leveroni Court Novato 94949 CA
   Company Phone Number: 483-8800   Stock Exchange / Ticker: NASDAQ RARE
   RARE is expected to report next financial results on November 01, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Immuron Limited

Immuron Limited reports decreased revenue and widened net loss in Q4 2023

In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.

Procyon Corporation

Observing the fourth quarter of 2023 numbers, Procyon Corporation reveals concerning revenue decline

Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.

Innovation Pharmaceuticals Inc

Revitalizing Growth: Innovation Pharmaceuticals Inc's Revenue Stagnant, But Positive Signs Emerge

Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.

Palatin Technologies Inc

Palatin Technologies Inc Defies the Odds with Explosive Revenue Growth in Q4 2023, While Major Pharmaceutical Preparations Companies Struggle to Turn Profitable

Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.

Ibio Inc

Ibio Inc's Fourth Quarter Earnings Show Alarming Surge in Losses and Share Value Decline

In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.


Ultragenyx Pharmaceutical Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com